{"answer":{"query":"Synjardy","resolved_as":"applications","packages":9,"applications":["NDA206111"],"identity":{"application_numbers":["NDA206111"],"marketing_categories":["NDA"],"labelers":[],"dosage_forms":[{"text":"TABLET","untrusted":true}],"marketing_start":{"earliest":"2015-09-12","latest":"2015-09-12","packages_with_a_start_date":9}},"generic_entry":[{"application":"NDA206111","date":"2034-11-17","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"9949997*PED","productNo":"004"},"latest_patent_expiry":"2034-11-17","latest_exclusivity_expiry":"2026-12-20","dated_barriers":104,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":14,"exclusivities_listed":2,"fact_id":"572bc731ba4dca6cc81a2746"}],"label_history":{"events_total":20,"non_cmc_events":19,"counts_by_class":{"LABELING":14,"EFFICACY":5},"cmc_events":1,"recent_non_cmc_events":[{"application":"NDA206111","submission_no":50,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-08-11","documents":[{"type":"Letter","date":"2026-08-14","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/201281Orig1s043;206111Orig1s050;208026Orig1s034;208658Orig1s038;212614Orig1s032ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-08-18","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206111s050lbl.pdf","untrusted":true}}],"fact_id":"8052010ea0cd3371032d5497"},{"application":"NDA206111","submission_no":46,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-10-24","documents":[{"type":"Label","date":"2025-10-27","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206111s046,208658s034lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-10-28","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/204629Orig1s063,206111Orig1s046,208658Orig1s034,206073Orig1s044,212614Orig1s029ltr.pdf","untrusted":true}}],"fact_id":"2be3920e10af13ae0a6e9a27"},{"application":"NDA206111","submission_no":45,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-03-07","documents":[{"type":"Letter","date":"2025-03-11","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/206111Orig1s045,208658Orig1s032ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-03-11","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206111s045,208658s032lbl.pdf","untrusted":true}}],"fact_id":"44537ad05d5aff42dea4a01b"},{"application":"NDA206111","submission_no":42,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-10-30","documents":[{"type":"Label","date":"2023-10-31","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206111s042,208658s028lbl.pdf","untrusted":true}},{"type":"Letter","date":"2023-10-31","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/206073Orig1s036; 206111Orig1s042; 208658Orig1s028; 212614Orig1s020ltr.pdf","untrusted":true}}],"fact_id":"fc03fe7fb86641cefbf3d26d"},{"application":"NDA206111","submission_no":39,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-06-20","documents":[{"type":"Label","date":"2023-06-22","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206111s038s039,208658s025s026lbl.pdf","untrusted":true}}],"fact_id":"4ffd9186f2a28171e3cce601"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":4,"te_code_counts":{"AB":4},"marketing_status_counts":{"Prescription":4},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA206111","product_no":"003","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"SYNJARDY","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"12.5MG;500MG","untrusted":true}},{"application":"NDA206111","product_no":"002","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"SYNJARDY","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"5MG;1GM","untrusted":true}},{"application":"NDA206111","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"SYNJARDY","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"5MG;500MG","untrusted":true}},{"application":"NDA206111","product_no":"004","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"SYNJARDY","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"12.5MG;1GM","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class II":1},"packages_of_these_applications":9,"most_recent":[{"recall_number":"D-1217-2018","classification":"Class II","status":"Terminated","report_date":"2018-10-03","recall_initiated":"2018-09-04","recalling_firm":{"text":"Boehringer Ingelheim Pharmaceuticals, Inc.","untrusted":true},"reason":{"text":"Cross Contamination With Other Products:","untrusted":true},"packages_named":9,"fact_id":"ee9fcbaaa73b20cf981487af"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"EMPAGLIFLOZIN","untrusted":true},"recruiting_interventional_count":94,"not_yet_recruiting_count":29,"by_phase":{"PHASE1/PHASE2":4,"PHASE3":18,"PHASE1":7,"PHASE4":29,"PHASE2":18,"EARLY_PHASE1":8,"NA":6,"PHASE2/PHASE3":4},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT03424005","title":{"text":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2018-03-30","link":{"text":"https://clinicaltrials.gov/study/NCT03424005","untrusted":true}},{"nct_id":"NCT05972564","title":{"text":"The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Vanderbilt University Medical Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2023-09-06","link":{"text":"https://clinicaltrials.gov/study/NCT05972564","untrusted":true}},{"nct_id":"NCT07038356","title":{"text":"Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Christian Schulze","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2025-12-08","link":{"text":"https://clinicaltrials.gov/study/NCT07038356","untrusted":true}},{"nct_id":"NCT07845630","title":{"text":"A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Boehringer Ingelheim","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-29","start_date":"2026-10-14","link":{"text":"https://clinicaltrials.gov/study/NCT07845630","untrusted":true}},{"nct_id":"NCT06249932","title":{"text":"Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"National Taiwan University Hospital","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-28","start_date":"2024-03-13","link":{"text":"https://clinicaltrials.gov/study/NCT06249932","untrusted":true}}],"fact_id":"ab0e426b6d1a73f39080ec45"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Teva Cares Foundation","untrusted":true},"type":"manufacturer","url":"https://www.tevacares.org/","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"Viatris (Mylan) Patient Assistance","untrusted":true},"type":"manufacturer","url":"https://www.viatris.com/en-us/lm/united-states/patient-assistance-program","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"Walmart $4 Prescriptions","untrusted":true},"type":"discount","url":"https://www.walmart.com/cp/4-dollar-prescriptions/1078664","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"Mark Cuban Cost Plus Drugs","untrusted":true},"type":"discount","url":"https://costplusdrugs.com/","status":null,"needs_status_check":false,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Empagliflozin/Metformin HCl","untrusted":true},"brand":{"text":"Synjardy","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":65861974.26,"claims":80720,"beneficiaries":17621,"average_spending_per_claim_usd":815.93129658,"fact_id":"6905094d2e874f91611c7e74"},{"year":2021,"gross_spending_usd":94402569.71,"claims":105016,"beneficiaries":23597,"average_spending_per_claim_usd":898.93511189,"fact_id":"4529e2bf1281a4068e2970dd"},{"year":2022,"gross_spending_usd":126415037.95,"claims":130200,"beneficiaries":29330,"average_spending_per_claim_usd":970.92963095,"fact_id":"13e7b5b2a404716ed4fc939c"},{"year":2023,"gross_spending_usd":163646663.37,"claims":157520,"beneficiaries":35768,"average_spending_per_claim_usd":1038.894511,"fact_id":"a87e73e5bfdc48760485a4a9"},{"year":2024,"gross_spending_usd":180248741.83,"claims":187400,"beneficiaries":42225,"average_spending_per_claim_usd":961.83960422,"fact_id":"bbb3945f794fd3877dd8c2ae"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"empagliflozin","untrusted":true},"designation_count":1,"approved_count":0,"recent":[{"designated":"2026-11-02","use":{"text":"treatment of glycogen storage disease type 1b (GSD1b)","untrusted":true},"status":"Designated","sponsor":{"text":"Vitalis Scientia LLC","untrusted":true},"approved":false}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"2bdcac1644e899b98d840283"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":8,"all_states_medicaid_reimbursed_usd":431220.09,"all_states_medicaid_paid_prescriptions":692,"top_states":[{"state":"KY","medicaid_paid_prescriptions":147,"medicaid_reimbursed_usd":118086.51,"total_reimbursed_usd":118086.51,"packages":1,"covers":"fee_for_service_only","fact_id":"46f6dd2c8d17c2a856354df0"},{"state":"PR","medicaid_paid_prescriptions":111,"medicaid_reimbursed_usd":69284.4,"total_reimbursed_usd":69284.4,"packages":1,"covers":"all_record_types","fact_id":"f726f1cb78c648bcfd4df24f"},{"state":"AL","medicaid_paid_prescriptions":107,"medicaid_reimbursed_usd":64366.48,"total_reimbursed_usd":66381.74,"packages":1,"covers":"all_record_types","fact_id":"884a46e7dffb6b9435f73441"},{"state":"WA","medicaid_paid_prescriptions":65,"medicaid_reimbursed_usd":53310.82,"total_reimbursed_usd":53310.82,"packages":1,"covers":"all_record_types","fact_id":"f651d82bf5f411a83d24a6b0"},{"state":"WI","medicaid_paid_prescriptions":82,"medicaid_reimbursed_usd":46757.56,"total_reimbursed_usd":49803.41,"packages":1,"covers":"all_record_types","fact_id":"e07e4ae6aef0baeb75a4ef44"},{"state":"AR","medicaid_paid_prescriptions":61,"medicaid_reimbursed_usd":37452.22,"total_reimbursed_usd":37452.22,"packages":1,"covers":"fee_for_service_only","fact_id":"4653a616bb8c9424faa2c0c6"},{"state":"TN","medicaid_paid_prescriptions":54,"medicaid_reimbursed_usd":32747.75,"total_reimbursed_usd":32885.75,"packages":1,"covers":"all_record_types","fact_id":"852d0184443123ef1f50a834"},{"state":"NV","medicaid_paid_prescriptions":65,"medicaid_reimbursed_usd":9214.35,"total_reimbursed_usd":9799.06,"packages":1,"covers":"fee_for_service_only","fact_id":"8565bbea7d6605f61db10007"}],"unlabelled_state_code_xx":null,"built_from_facts":8,"facts_fee_for_service_only":3,"older_year_facts_not_used":135,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"7487ec012c6619d1429a730c","field":"ndc.listing","entity":"ndc:00597015918"},{"fact_id":"519ff120ee4cf92af73e3813","field":"ndc.listing","entity":"ndc:00597015960"},{"fact_id":"7008a97ff15d0c3ea9b25cb7","field":"ndc.listing","entity":"ndc:00597016818"},{"fact_id":"572bc731ba4dca6cc81a2746","field":"drug.generic_entry_earliest","entity":"application:NDA206111"},{"fact_id":"59175a89de0e7c55320ac2f5","field":"drug.patent","entity":"application:NDA206111"},{"fact_id":"c97080fa30451f1b5d4f55b6","field":"drug.exclusivity","entity":"application:NDA206111"},{"fact_id":"8052010ea0cd3371032d5497","field":"drug.label_event","entity":"application:NDA206111"},{"fact_id":"2be3920e10af13ae0a6e9a27","field":"drug.label_event","entity":"application:NDA206111"},{"fact_id":"44537ad05d5aff42dea4a01b","field":"drug.label_event","entity":"application:NDA206111"},{"fact_id":"fc03fe7fb86641cefbf3d26d","field":"drug.label_event","entity":"application:NDA206111"},{"fact_id":"4ffd9186f2a28171e3cce601","field":"drug.label_event","entity":"application:NDA206111"},{"fact_id":"d21821940b535315dde1d145","field":"drug.te_code","entity":"application:NDA206111"},{"fact_id":"1c3e7c07616ed4fbc772ae38","field":"drug.marketing_status","entity":"application:NDA206111"},{"fact_id":"84e24ec8bebcbd2cb7a50634","field":"drug.te_code","entity":"application:NDA206111"},{"fact_id":"87c36a921bce6e7f040044f0","field":"drug.marketing_status","entity":"application:NDA206111"},{"fact_id":"6ae1e3f2598d6bbfa273a999","field":"drug.te_code","entity":"application:NDA206111"},{"fact_id":"177a6c1cc882fed091bb823e","field":"drug.marketing_status","entity":"application:NDA206111"},{"fact_id":"0486c8c5a261b85d8caba9fb","field":"drug.te_code","entity":"application:NDA206111"},{"fact_id":"e4387b79d2cd181dff596ec2","field":"drug.marketing_status","entity":"application:NDA206111"},{"fact_id":"ee9fcbaaa73b20cf981487af","field":"ndc.recall","entity":"ndc:00597016866"},{"fact_id":"ab0e426b6d1a73f39080ec45","field":"drug.trial_access","entity":"drug:empagliflozin"},{"fact_id":"6905094d2e874f91611c7e74","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy"},{"fact_id":"4529e2bf1281a4068e2970dd","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy"},{"fact_id":"13e7b5b2a404716ed4fc939c","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy"},{"fact_id":"a87e73e5bfdc48760485a4a9","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy"},{"fact_id":"bbb3945f794fd3877dd8c2ae","field":"drug.partd_spending","entity":"drug:empagliflozin-metformin-hcl|synjardy"},{"fact_id":"2bdcac1644e899b98d840283","field":"drug.orphan_designation","entity":"drug:empagliflozin"},{"fact_id":"46f6dd2c8d17c2a856354df0","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597017560:KY"},{"fact_id":"f726f1cb78c648bcfd4df24f","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597018018:PR"},{"fact_id":"884a46e7dffb6b9435f73441","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597018060:AL"},{"fact_id":"f651d82bf5f411a83d24a6b0","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597017560:WA"},{"fact_id":"e07e4ae6aef0baeb75a4ef44","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597017560:WI"},{"fact_id":"4653a616bb8c9424faa2c0c6","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597016818:AR"},{"fact_id":"852d0184443123ef1f50a834","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597017560:TN"},{"fact_id":"8565bbea7d6605f61db10007","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597016818:NV"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price","reason":"no NADAC price, negotiated price or federal upper limit for these packages"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}